Lebrikizumab is an interleukin-13 antagonist approved as Ebglyss for the treatment of adults and pediatric patients with moderate to severe atopic dermatitis.

The data suggest significant challenges in maintaining long-term disease control with advanced systemic therapies for atopic dermatitis.

The six-time PGA Tour winner once suffered from seborrheic dermatitis, a chronic inflammatory disease that causes dandruff, redness and plaques in the scalp, fa ...

A 91-year-old man with a history of bladder carcinoma and left total knee arthroplasty was evaluated because of left knee pain. A culture of synovial fluid showed no growth. A diagnosis was made.

Conservative management remains the foundation of chronic venous insufficiency care and reduces the risk for ulceration when initiated early.

- Company to hold conference call and webcast at 8:30 a.m. ET today Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies ...

A fast CME slammed into Earth on Jan. 19, unleashing hours of intense auroral activity and lighting up skies far beyond the poles. When you purchase through links on our site, we may earn an affiliate ...

Severe weather will be possible in Alabama on Friday, and forecasters now think Saturday could bring a few severe storms as well. There will be a Level 2 out of 5 severe weather risk for parts of ...

The researchers noted that "altered iron metabolism may represent a potentially modifiable systemic correlate of the AD phenotypes." HealthDay News — Iron deficiency without anemia is a common feature ...

Also called eczema, atopic dermatitis is estimated to affect 10 to 20 percent of children, usually babies or very young kids, although it can last past adolescence and into adulthood. The skin ...

HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development ...